Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine
May 20, 2021 Vol. 384 No. 20
http://www.nejm.org/toc/nejm/medical-journal

 

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Vivek Shinde, M.D., M.P.H., et al for the 2019nCoV-501 Study Group*
Conclusions
The NVX-CoV2373 vaccine was efficacious in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant. (Funded by Novavax and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT04533399. opens in new tab.)